PT2196199E - Tratamento de fenómenos fantasma - Google Patents
Tratamento de fenómenos fantasma Download PDFInfo
- Publication number
- PT2196199E PT2196199E PT101584043T PT10158404T PT2196199E PT 2196199 E PT2196199 E PT 2196199E PT 101584043 T PT101584043 T PT 101584043T PT 10158404 T PT10158404 T PT 10158404T PT 2196199 E PT2196199 E PT 2196199E
- Authority
- PT
- Portugal
- Prior art keywords
- bdnf
- signal transduction
- phantom
- transduction cascade
- antagonist
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0046—Ear
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102005004343A DE102005004343A1 (de) | 2005-01-25 | 2005-01-25 | Behandlung von Phantomphänomenen |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT2196199E true PT2196199E (pt) | 2014-09-09 |
Family
ID=36123208
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT101584043T PT2196199E (pt) | 2005-01-25 | 2006-01-19 | Tratamento de fenómenos fantasma |
| PT06706302T PT1843757E (pt) | 2005-01-25 | 2006-01-19 | Tratamento de fenëmenos fantasma |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT06706302T PT1843757E (pt) | 2005-01-25 | 2006-01-19 | Tratamento de fenëmenos fantasma |
Country Status (11)
| Country | Link |
|---|---|
| US (4) | US20080255096A1 (pt) |
| EP (2) | EP2196199B9 (pt) |
| AT (1) | ATE462422T1 (pt) |
| CY (1) | CY1115638T1 (pt) |
| DE (2) | DE102005004343A1 (pt) |
| DK (2) | DK1843757T3 (pt) |
| ES (2) | ES2343691T3 (pt) |
| PL (2) | PL2196199T3 (pt) |
| PT (2) | PT2196199E (pt) |
| SI (2) | SI1843757T1 (pt) |
| WO (1) | WO2006079476A1 (pt) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102007063210A1 (de) | 2007-12-20 | 2009-06-25 | Eberhard-Karls-Universität Tübingen Universitätsklinikum | Arzneimittel zur Behandlung von Phantomphänomenen |
| ES2862673T3 (es) | 2011-12-12 | 2021-10-07 | Zilentin AG | Tratamiento del tinnitus mediante la modulación del cotransportador de cloruro NKCC1 en el sistema auditivo |
| US10066229B2 (en) * | 2015-07-28 | 2018-09-04 | Otonomy, Inc. | Treatment using truncated Trk B and Trk C antagonists |
| US10071083B2 (en) | 2017-02-03 | 2018-09-11 | Ovid Therapeutics Inc | Use of gaboxadol in the treatment of tinnitus |
| GB2571696B (en) | 2017-10-09 | 2020-05-27 | Compass Pathways Ltd | Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced |
| US10765666B2 (en) | 2018-09-20 | 2020-09-08 | Ovid Therapeutics Inc | Use of gaboxadol for the treatment of Tourette syndrome, tics and stuttering |
| US11690829B2 (en) | 2018-12-17 | 2023-07-04 | Ovid Therapeutics Inc. | Use of gaboxadol for the treatment of non-24 hour sleep-wake disorder |
| WO2020212948A1 (en) | 2019-04-17 | 2020-10-22 | Compass Pathfinder Limited | Methods of treating neurocognitive disorders, chronic pain and reducing inflammation |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3254124A (en) * | 1962-06-29 | 1966-05-31 | Parke Davis & Co | Aminoketones and methods for their production |
| US4954486A (en) * | 1985-06-05 | 1990-09-04 | Tulane Educational Fund | Furosemide as tinnitus suppressant |
| WO1994008599A1 (en) * | 1992-10-14 | 1994-04-28 | The Regents Of The University Of Colorado | Ion-pairing of drugs for improved efficacy and delivery |
| US5421818A (en) * | 1993-10-18 | 1995-06-06 | Inner Ear Medical Delivery Systems, Inc. | Multi-functional inner ear treatment and diagnostic system |
| WO1996009044A1 (en) * | 1994-09-22 | 1996-03-28 | Richard Alan Smith | Compositions useful for the preparation of medicines for treating a variety of intractable disorders |
| DE19528388A1 (de) * | 1995-08-02 | 1997-02-06 | Hans Peter Prof Dr Med Zenner | Verwendung von Adamantan-Derivaten zur Behandlung von Erkrankungen des Innenohrs |
| US6225282B1 (en) * | 1996-01-05 | 2001-05-01 | Genentech, Inc. | Treatment of hearing impairments |
| AU2676397A (en) * | 1996-04-18 | 1997-11-07 | University Technology Corporation | Methods for treating middle and inner ear disorders |
| US6045528A (en) * | 1997-06-13 | 2000-04-04 | Intraear, Inc. | Inner ear fluid transfer and diagnostic system |
| US6309410B1 (en) * | 1998-08-26 | 2001-10-30 | Advanced Bionics Corporation | Cochlear electrode with drug delivery channel and method of making same |
| DE19853299C2 (de) * | 1998-11-19 | 2003-04-03 | Thomas Lenarz | Katheter zur Applikation von Medikamenten in Flüssigkeitsräumen des menschlichen Innenohrs |
| US6120484A (en) * | 1999-02-17 | 2000-09-19 | Silverstein; Herbert | Otological implant for delivery of medicament and method of using same |
| US6017961A (en) * | 1999-07-08 | 2000-01-25 | Flores; John Anthony | Ketamine and n-butyl-p-aminobezoate in PLO |
| DE10048969A1 (de) * | 2000-08-23 | 2002-03-14 | Mueller Schwefe Gerhard | Verwendung von Flupirtin zur Tinnitusbehandlung |
| DE10124953A1 (de) * | 2001-05-21 | 2002-12-12 | Marlies Knipper | Substanz für die therapeutische Behandlung von Tinnitus |
| US6638981B2 (en) * | 2001-08-17 | 2003-10-28 | Epicept Corporation | Topical compositions and methods for treating pain |
| EP1545551A4 (en) * | 2002-09-06 | 2008-10-22 | Durect Corp | DISTRIBUTION OF MODULATORS OF THE GLUTAMAT-MEDIATED NEUROTRANSMISSION TO THE INNER EAR |
| US6656172B1 (en) * | 2002-09-27 | 2003-12-02 | Medtronic, Inc. | Method for treating severe tinnitus |
| US6969383B2 (en) * | 2002-09-27 | 2005-11-29 | Medtronic, Inc. | Method for treating severe tinnitus |
| DE602004023832D1 (de) * | 2003-05-16 | 2009-12-10 | Univ Laval | Cns chlorid-modulierung und verwendung derselben |
| US7196061B2 (en) * | 2003-09-10 | 2007-03-27 | Wyeth | Compounds that modulate neuronal growth and their uses |
| GB0402118D0 (en) * | 2004-01-30 | 2004-03-03 | Merck Sharp & Dohme | Polymorphic forms of a GABAA agonist |
-
2005
- 2005-01-25 DE DE102005004343A patent/DE102005004343A1/de not_active Ceased
-
2006
- 2006-01-19 SI SI200630697T patent/SI1843757T1/sl unknown
- 2006-01-19 EP EP10158404.3A patent/EP2196199B9/de active Active
- 2006-01-19 DE DE502006006576T patent/DE502006006576D1/de active Active
- 2006-01-19 DK DK06706302.4T patent/DK1843757T3/da active
- 2006-01-19 SI SI200631820T patent/SI2196199T1/sl unknown
- 2006-01-19 DK DK10158404.3T patent/DK2196199T3/da active
- 2006-01-19 ES ES06706302T patent/ES2343691T3/es active Active
- 2006-01-19 EP EP06706302A patent/EP1843757B1/de not_active Not-in-force
- 2006-01-19 WO PCT/EP2006/000446 patent/WO2006079476A1/de active Application Filing
- 2006-01-19 US US11/814,663 patent/US20080255096A1/en not_active Abandoned
- 2006-01-19 PL PL10158404T patent/PL2196199T3/pl unknown
- 2006-01-19 PT PT101584043T patent/PT2196199E/pt unknown
- 2006-01-19 AT AT06706302T patent/ATE462422T1/de active
- 2006-01-19 ES ES10158404.3T patent/ES2521519T3/es active Active
- 2006-01-19 PL PL06706302T patent/PL1843757T3/pl unknown
- 2006-01-19 PT PT06706302T patent/PT1843757E/pt unknown
-
2012
- 2012-06-18 US US13/526,185 patent/US20120302554A1/en not_active Abandoned
-
2014
- 2014-10-16 CY CY20141100852T patent/CY1115638T1/el unknown
- 2014-12-16 US US14/572,376 patent/US20150099742A1/en not_active Abandoned
-
2016
- 2016-11-04 US US15/343,817 patent/US20170072007A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CY1115638T1 (el) | 2017-01-04 |
| DE102005004343A1 (de) | 2006-08-10 |
| EP1843757B1 (de) | 2010-03-31 |
| US20120302554A1 (en) | 2012-11-29 |
| SI1843757T1 (sl) | 2010-09-30 |
| WO2006079476A1 (de) | 2006-08-03 |
| DE502006006576D1 (de) | 2010-05-12 |
| EP2196199B1 (de) | 2014-08-13 |
| ATE462422T1 (de) | 2010-04-15 |
| EP1843757A1 (de) | 2007-10-17 |
| DK2196199T3 (da) | 2014-11-03 |
| DK1843757T3 (da) | 2010-07-26 |
| EP2196199B8 (de) | 2014-09-24 |
| US20150099742A1 (en) | 2015-04-09 |
| PT1843757E (pt) | 2010-07-06 |
| ES2343691T3 (es) | 2010-08-06 |
| EP2196199B9 (de) | 2014-12-31 |
| SI2196199T1 (sl) | 2014-12-31 |
| ES2521519T9 (es) | 2015-04-07 |
| US20170072007A1 (en) | 2017-03-16 |
| PL2196199T3 (pl) | 2015-01-30 |
| EP2196199A1 (de) | 2010-06-16 |
| ES2521519T3 (es) | 2014-11-12 |
| PL1843757T3 (pl) | 2010-09-30 |
| US20080255096A1 (en) | 2008-10-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1115638T1 (el) | Θεραπεια ψευδαισθητικων φαινομενων | |
| Rueter et al. | A critical review of 5-HT brain microdialysis and behavior | |
| Argoff et al. | Multimodal analgesia for chronic pain: rationale and future directions | |
| Heimrath et al. | Transcranial direct current stimulation (tDCS) traces the predominance of the left auditory cortex for processing of rapidly changing acoustic information | |
| ATE537872T1 (de) | Gerät zur behandlung von neurologischen störungen mit chronisch adaptiver gehirn-stimulation in abhängigkeit von lokalen biopotentialen | |
| EA201000245A1 (ru) | Человеческие нейтрализующие антитела к фактору роста нервов (ngf) в качестве селективных ингибиторов метаболического пути ngf | |
| WO2004078252A3 (en) | Multi-channel and multi-dimensional system and method | |
| WO2004045391A3 (en) | Methods and systems for using transcranial magnetic stimulation and functional brain mapping for examining cortical sensitivity, brain communication, and effects of medication | |
| EA200600920A1 (ru) | Иммуносорбентные исследования крови для оценки пароксизмальных церебральных разрядов | |
| US20040092504A1 (en) | Definitive medications for treating fibromyalgia | |
| Petrucci et al. | Post-ictal generalized EEG suppression is reduced by enhancing dorsal raphe serotonergic neurotransmission | |
| Liu et al. | Effects of salicylate on serotoninergic activities in rat inferior colliculus and auditory cortex | |
| EP1466576A1 (en) | Method and apparatus for using a varying frequency signal to stimulate the human body | |
| Takatsuji et al. | Induction of the swallowing reflex by electrical stimulation of the posterior oropharyngeal region in awake humans | |
| Ramsey et al. | 5-HT1A and 5-HT1B receptors differentially modulate rate and timing of auditory responses in the mouse inferior colliculus | |
| Miyazato et al. | Locus coeruleus involvement in the effects of immobilization stress on the p13 midlatency auditory evoked potential in the rat | |
| Robert et al. | In vivo effects of serotonin and fluoxetine on cardio-ventilatory functions in the shore crab Carcinus maenas (L. 1758) | |
| Yoshida et al. | The possible effect of nitric oxide on relaxation and noradrenaline release in the isolated rabbit urethra | |
| Schneider et al. | Optimized Electrical Stimulation of C-Nociceptors in Humans Based on the Chronaxie of Porcine C-Fibers | |
| DK2024388T3 (da) | Peptidsubstans, der stimulerer neuroner hos det centrale nervesystem, farmaceutisk komposition med dens base og fremgangsmåde til applicering deraf | |
| Talimkhani et al. | Differential Effects of Unihemispheric Concurrent Dualsite and Conventional Primary Motor Cortex Transcranial Direct Current Stimulation on Motor Sequence Learning in Healthy Individuals: A Randomized Sham-Controlled Study | |
| RU2377562C1 (ru) | Способ определения биологической активности воды | |
| WO2004053107A3 (en) | Methods for treating diabetes | |
| Akçay | Investigation of the learning and memory enhancing effects of 0.25 ma and 0.5 ma anodal and cathodal transcranial direct current stimulations in healthy rats | |
| Hallock et al. | Effects of electrical stimulation of the glossopharyngeal nerve on cells in the nucleus of the solitary tract of the rat |